Resmed shares have climbed, with the medical device-maker saying Ozempic-style weight loss drugs appear to be having the opposite effect on its sales than many expected.
As GLP-1 drugs like Wegovy and Mounjaro surged in popularity a few years ago, some investors feared they would reduce demand for the Resmed's devices, leading to RMD shares falling by nearly a quarter in August 2023.
